On the Precipice of a "Rituximab-Like" Era for T-cell Lymphomas?

To date monoclonal antibodies have had limited success in improving outcomes for patients with T-cell lymphomas. Preclinical data suggests that anti-T-cell Receptor Vβ-segment monoclonal antibodies are a novel therapeutic strategy for patients with T-cell lymphomas that avoid several limitations of current therapies.